{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:22:24Z","timestamp":1784308944107,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Colloid and Interface Science"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jcis.2023.06.030","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T08:58:56Z","timestamp":1686387536000},"page":"929-942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Synergistic therapeutic antitumor effect of PD-1 blockade cellular vesicles in combination with Iguratimod and Rhodium nanoparticles"],"prefix":"10.1016","volume":"649","author":[{"given":"Muhammad","family":"Younis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongyan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcis.2023.06.030_b0005","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell."},{"issue":"7378","key":"10.1016\/j.jcis.2023.06.030_b0010","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature."},{"issue":"7528","key":"10.1016\/j.jcis.2023.06.030_b0015","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature."},{"key":"10.1016\/j.jcis.2023.06.030_b0020","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7\u2013H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med."},{"issue":"26","key":"10.1016\/j.jcis.2023.06.030_b0025","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"The New England journal of medicine."},{"issue":"4","key":"10.1016\/j.jcis.2023.06.030_b0030","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"The New England journal of medicine."},{"issue":"27","key":"10.1016\/j.jcis.2023.06.030_b0035","doi-asserted-by":"crossref","first-page":"10980","DOI":"10.1073\/pnas.1106634108","article-title":"Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform","volume":"108","author":"Hu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"8","key":"10.1016\/j.jcis.2023.06.030_b0040","doi-asserted-by":"crossref","first-page":"863","DOI":"10.7150\/thno.11852","article-title":"Cell or cell membrane-based drug delivery systems","volume":"5","author":"Tan","year":"2015","journal-title":"Theranostics."},{"issue":"1","key":"10.1016\/j.jcis.2023.06.030_b0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/nrc.2015.3","article-title":"Biomaterials and emerging anticancer therapeutics: engineering the microenvironment","volume":"16","author":"Gu","year":"2016","journal-title":"Nature reviews Cancer."},{"key":"10.1016\/j.jcis.2023.06.030_b0050","doi-asserted-by":"crossref","first-page":"107219","DOI":"10.1016\/j.intimp.2020.107219","article-title":"Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-\u03b1 signaling pathways","volume":"90","author":"Li","year":"2021","journal-title":"International immunopharmacology."},{"key":"10.1016\/j.jcis.2023.06.030_b0055","doi-asserted-by":"crossref","first-page":"102101","DOI":"10.1016\/j.nano.2019.102101","article-title":"Iguratimod encapsulated PLGA-NPs improves therapeutic outcome in glioma, glioma stem-like cells and temozolomide resistant glioma cells","volume":"22","author":"Younis","year":"2019","journal-title":"Nanomedicine : nanotechnology, biology, and medicine."},{"key":"10.1016\/j.jcis.2023.06.030_b0060","doi-asserted-by":"crossref","first-page":"107532","DOI":"10.1016\/j.intimp.2021.107532","article-title":"Iguratimod-encapsulating PLGA-NPs induce human multiple myeloma cell death via reactive oxygen species and Caspase-dependent signalling","volume":"95","author":"Wang","year":"2021","journal-title":"International immunopharmacology."},{"issue":"7","key":"10.1016\/j.jcis.2023.06.030_b0065","first-page":"6997","article-title":"Morphology-Controlled Synthesis of Rhodium Nanoparticles for Cancer Phototherapy","volume":"12","author":"Kang","year":"2018","journal-title":"Morphology-Controlled Synthesis of Rhodium Nanoparticles for Cancer Phototherapy."},{"key":"10.1016\/j.jcis.2023.06.030_b0070","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jcis.2023.01.068","article-title":"Design and synthesis of cancer-cell-membrane-camouflaged hemoporfin-Cu9S8 nanoagents for homotypic tumor-targeted photothermal-sonodynamic therapy","volume":"637","author":"Zhao","year":"2023","journal-title":"Journal of colloid and interface science."},{"key":"10.1016\/j.jcis.2023.06.030_b0075","unstructured":"Li M, Zhang X, Wang M, Wang Y, Qian J, Xing X, et al. Activation of Piezo1 contributes to matrix stiffness-induced angiogenesis in hepatocellular carcinoma. Cancer Communications. n\/a."},{"issue":"31","key":"10.1016\/j.jcis.2023.06.030_b0080","doi-asserted-by":"crossref","first-page":"26056","DOI":"10.1021\/acsami.8b08975","article-title":"Real-Time Multimodal Bioimaging of Cancer Cells and Exosomes through Biosynthesized Iridium and Iron Nanoclusters","volume":"10","author":"Shaikh","year":"2018","journal-title":"ACS applied materials & interfaces."},{"issue":"32","key":"10.1016\/j.jcis.2023.06.030_b0085","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.1021\/acs.langmuir.0c01378","article-title":"Specific Oxide Nanoclusters Enhance Intracellular Reactive Oxygen Species for Cancer-Targeted Therapy","volume":"36","author":"Shaikh","year":"2020","journal-title":"Langmuir."},{"key":"10.1016\/j.jcis.2023.06.030_b0090","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jcis.2022.06.008","article-title":"Biomimetic metal\u2013organic frameworks navigated biological bombs for efficient lung cancer therapy","volume":"625","author":"Yang","year":"2022","journal-title":"Journal of colloid and interface science."},{"issue":"4","key":"10.1016\/j.jcis.2023.06.030_b0095","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1021\/nl500618u","article-title":"Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery","volume":"14","author":"Fang","year":"2014","journal-title":"Nano letters."},{"issue":"7655","key":"10.1016\/j.jcis.2023.06.030_b0100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature."},{"issue":"2","key":"10.1016\/j.jcis.2023.06.030_b0105","first-page":"280","article-title":"Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1","volume":"41","author":"Shin","year":"2022","journal-title":"Oncogenic KRAS promotes growth of lung cancer cells expressing SLC3A2-NRG1 fusion via ADAM17-mediated shedding of NRG1."},{"issue":"8","key":"10.1016\/j.jcis.2023.06.030_b0110","first-page":"2002404","article-title":"Dose\u2010Dependent Carbon\u2010Dot\u2010Induced ROS Promote Uveal Melanoma Cell Tumorigenicity via Activation of mTOR Signaling and Glutamine Metabolism","volume":"8","author":"Ding","year":"2021","journal-title":"Dose-Dependent Carbon-Dot-Induced ROS Promote Uveal Melanoma Cell Tumorigenicity via Activation of mTOR Signaling and Glutamine Metabolism."},{"issue":"26","key":"10.1016\/j.jcis.2023.06.030_b0115","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"The New England journal of medicine."},{"issue":"2","key":"10.1016\/j.jcis.2023.06.030_b0120","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer research."},{"issue":"18","key":"10.1016\/j.jcis.2023.06.030_b0125","first-page":"e108647","article-title":"Dynamic EMT: a multi\u2010tool for tumor progression","volume":"40","author":"Brabletz","year":"2021","journal-title":"Dynamic EMT: a multi-tool for tumor progression."},{"issue":"5","key":"10.1016\/j.jcis.2023.06.030_b0130","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ceb.2005.08.001","article-title":"Molecular requirements for epithelial-mesenchymal transition during tumor progression","volume":"17","author":"Huber","year":"2005","journal-title":"Current opinion in cell biology."},{"key":"10.1016\/j.jcis.2023.06.030_b0135","first-page":"3650","article-title":"Cadherin switching in human prostate cancer progression","volume":"60","author":"Tomita","year":"2000","journal-title":"Cancer research."},{"issue":"3","key":"10.1016\/j.jcis.2023.06.030_b0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cell.2004.07.011","article-title":"Epithelial-mesenchymal transitions: twist in development and metastasis","volume":"118","author":"Kang","year":"2004","journal-title":"Cell."},{"issue":"12","key":"10.1016\/j.jcis.2023.06.030_b0145","first-page":"4125","article-title":"N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clinical cancer research : an official journal of the American Association for","volume":"10","author":"Nakajima","year":"2004","journal-title":"Cancer Research."},{"key":"10.1016\/j.jcis.2023.06.030_b0150","doi-asserted-by":"crossref","first-page":"101156","DOI":"10.1016\/j.nantod.2021.101156","article-title":"Recent advances in optical imaging of biomarkers in vivo","volume":"38","author":"Meng","year":"2021","journal-title":"Nano Today."},{"key":"10.1016\/j.jcis.2023.06.030_b0155","doi-asserted-by":"crossref","first-page":"101035","DOI":"10.1016\/j.nantod.2020.101035","article-title":"Nanotechnology enabled reactive species regulation in biosystems for boosting cancer immunotherapy","volume":"36","author":"Zhang","year":"2021","journal-title":"Nano Today."},{"key":"10.1016\/j.jcis.2023.06.030_b0160","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bioactmat.2022.05.015","article-title":"Biomimetic AgNPs@antimicrobial peptide\/silk fibroin coating for infection-trigger antibacterial capability and enhanced osseointegration","volume":"20","author":"Zhou","year":"2023","journal-title":"Bioactive Materials."},{"key":"10.1016\/j.jcis.2023.06.030_b0165","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.redox.2015.07.008","article-title":"Antioxidant responses and cellular adjustments to oxidative stress","volume":"6","author":"Espinosa-Diez","year":"2015","journal-title":"Redox biology."},{"key":"10.1016\/j.jcis.2023.06.030_b0170","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bioactmat.2022.05.017","article-title":"Anti-oxidant anti-inflammatory and antibacterial tannin-crosslinked citrate-based mussel-inspired bioadhesives facilitate scarless wound healing","volume":"20","author":"Wu","year":"2023","journal-title":"Bioactive Materials."},{"key":"10.1016\/j.jcis.2023.06.030_b0175","doi-asserted-by":"crossref","first-page":"215594","DOI":"10.1016\/j.canlet.2022.215594","article-title":"Arginine methyltransferase PRMT5 methylates and destabilizes Mxi1 to confer radioresistance in non-small cell lung cancer","volume":"532","author":"Yang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jcis.2023.06.030_b0180","doi-asserted-by":"crossref","first-page":"215886","DOI":"10.1016\/j.canlet.2022.215886","article-title":"Blood protein biomarkers in lung cancer","volume":"551","author":"Huang","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jcis.2023.06.030_b0185","first-page":"1","article-title":"Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of","volume":"2016","author":"Jakubowska","year":"2016","journal-title":"Pancreatic Ductal Adenocarcinoma."},{"key":"10.1016\/j.jcis.2023.06.030_b0190","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunological reviews."},{"issue":"4","key":"10.1016\/j.jcis.2023.06.030_b0195","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nature reviews Cancer."},{"key":"10.1016\/j.jcis.2023.06.030_b0200","doi-asserted-by":"crossref","first-page":"215867","DOI":"10.1016\/j.canlet.2022.215867","article-title":"FGFR1\/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression","volume":"547","author":"Hu","year":"2022","journal-title":"Cancer Letters."},{"key":"10.1016\/j.jcis.2023.06.030_b0205","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2021.09.039","article-title":"Tumor-derived microparticles promote the progression of triple-negative breast cancer via PD-L1-associated immune suppression","volume":"523","author":"Li","year":"2021","journal-title":"Cancer Letters."},{"issue":"1","key":"10.1016\/j.jcis.2023.06.030_b0210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-014-2988-5","article-title":"Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer","volume":"146","author":"Muenst","year":"2014","journal-title":"Breast cancer research and treatment."},{"issue":"7","key":"10.1016\/j.jcis.2023.06.030_b0215","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","article-title":"Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer","volume":"13","author":"Nomi","year":"2007","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research."},{"issue":"1","key":"10.1016\/j.jcis.2023.06.030_b0220","article-title":"Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-\u03b2 type II receptor signaling","volume":"13","author":"Xie","year":"2022","journal-title":"Breast cancer cell-derived extracellular vesicles promote CD8(+) T cell exhaustion via TGF-\u03b2 type II receptor signaling."},{"issue":"1","key":"10.1016\/j.jcis.2023.06.030_b0225","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccell.2021.11.012","article-title":"Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance","volume":"40","author":"Newell","year":"2022","journal-title":"Cancer cell."},{"key":"10.1016\/j.jcis.2023.06.030_b0230","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcis.2022.02.050","article-title":"Ag nanoparticles enhance immune checkpoint blockade efficacy by promoting of immune surveillance in melanoma","volume":"616","author":"Kuang","year":"2022","journal-title":"Journal of colloid and interface science."},{"key":"10.1016\/j.jcis.2023.06.030_b0235","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jcis.2023.01.091","article-title":"Programmed-stimuli responsive carrier-free multidrug delivery system for highly efficient trimodal combination therapy","volume":"637","author":"Zhou","year":"2023","journal-title":"Journal of colloid and interface science."},{"issue":"1","key":"10.1016\/j.jcis.2023.06.030_b0240","article-title":"Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment","volume":"13","author":"Reda","year":"2022","journal-title":"Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment."}],"container-title":["Journal of Colloid and Interface Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021979723010408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021979723010408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:10:34Z","timestamp":1758273034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021979723010408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":48,"alternative-id":["S0021979723010408"],"URL":"https:\/\/doi.org\/10.1016\/j.jcis.2023.06.030","relation":{},"ISSN":["0021-9797"],"issn-type":[{"value":"0021-9797","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic therapeutic antitumor effect of PD-1 blockade cellular vesicles in combination with Iguratimod and Rhodium nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Journal of Colloid and Interface Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcis.2023.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}